The GLP-1 Era and the Making of Medical Fitness

State of play

The GLP-1 economy has stopped being a forecast and become the pharmaceutical market’s engine. Evaluate’s 2026 preview projects Eli Lilly’s tirzepatide — sold as Mounjaro and Zepbound — to take more than $45 billion in global sales this year, making it the world’s top-selling drug, with Novo Nordisk’s semaglutide franchise projected at $39.5 billion. The quarterly prints back the projection. Lilly’s Q2 2026 revenue rose 48% to $22.97 billion, with Mounjaro at $9.9 billion and Zepbound at $4.9 billion — a combined $14.871 billion — and the company raised full-year guidance to $85-87 billion. Novo Nordisk reported Q2 net sales of DKK 78,488 million and said its Wegovy pill, approved by Europe’s regulator in July with up to 16.6% mean weight loss, exceeded 265,000 weekly US prescriptions in mid-July and has passed 5 million prescriptions since launch. Novo also raised its full-year outlook on the strength of GLP-1 expectations — adjusted sales growth guidance of 0% to -6% at constant exchange rates — while the efficacy ceiling kept rising: the 7.2 mg dose has shown up to 20.7% mean weight loss in trials.

Why it matters

The fear that drugs would empty gym floors has given way to something more commercially useful: operators redesigning programming for a medicated membership. Orangetheory’s survey data found more than half of GLP-1 users say medication alone is not enough for lasting transformation, and the brand has responded by emphasizing resistance training and metabolic health — a direct answer to muscle loss on these drugs and to the habit problem its fitness leadership describes when noting the medications don’t teach consistency, confidence or stress management. That is the commercial logic of the era: a prescription creates a member with a defined physiological need — preserved lean mass, rebuilt routine, managed recovery — that a gym is unusually well placed to serve. The muscle-preservation angle converts a churn threat into a programming mandate, and the prescriptions boom is pulling fitness into medical referral pathways that did not exist two years ago. The counterweight sits in the data: weight regain after stopping GLP-1s often begins faster than after ending diet or exercise programs, which is precisely why operators who own the behavior-change layer — coaching, community, progressive resistance training — have a durable role in a medicated market rather than a redundant one.

Momentum call: rising, dated 2 November 2026 — prescription volume, guidance upgrades and operator program redesign are all accelerating in the same direction.

What to watch

• Whether oral dosing widens the funnel: EMA approval opens European markets where injectables stalled.
• Muscle-preservation programming becoming standard onboarding for members who disclose GLP-1 use.
• Employer and insurer coverage decisions that would formalize exercise as the adjunct therapy the data implies.
• The second-order churn question: what retention looks like when users cycle off the drugs and regain begins.